Homepage - Ipsen Group

News

10 / 10 / 2017

Dr Sotirios Stergiopoulos appointed as the new President of the Board of Governors of Accreditation Council for Medical Affairs (ACMA).

Press releases

Learn more

16 / 10 / 2017

Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall surv...

19 / 09 / 2017

Ipsen receives approval from European Commission for Xermelo® (telotristat ethyl) for the treatme...

18 / 09 / 2017

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for th...

Twitter

@IpsenGroup RT @G5Sante: @garidel_de : "Très bonne chose que nouvelle Ministre de la santé @agnesbuzyn connaisse parfaitement monde santé & recherche"… 2017 Oct, 18 15:49
@IpsenGroup RT @G5Sante: T.Eckenschwiller (Ipsen Italie) : L'Italie a pour ambition de devenir 1er pays UE pour la production #pharma en Europe, devant… 2017 Oct, 18 9:57
@IpsenGroup #phase3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced #HCC https://t.co/TcR1dTI3It 2017 Oct, 16 13:21
@IpsenGroup #BREAKINGNEWS We are excited to continue membership w/ @PhRMA to boost R&D efforts for more innovative patient care… https://t.co/jLHtL0lvkC 2017 Oct, 11 22:39

Executive Leadership Team

David Meek Executive Leadership Team

The Executive Leadership Team leads the Group business, in the areas of scientific, legal, financial, commercial and strategic matters.

Learn more

FACTS AND FIGURES 2016

Registration Document
Read
Download

Annual report 2016
Read
Download

RESEARCH & DEVELOPMENT

Ipsen’s commitment in research & development is our bold promise to patients, to launch at least one new drug or meaningful new indication every year.

Find a clinical trial >

Learn more